Phathom Pharmaceuticals
PHAT
84 hedge funds and large institutions have $220M invested in Phathom Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 18 closing their positions.
11,188% more call options, than puts
Call options by funds: $1.81M | Put options by funds: $16K
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
5.56% more ownership
Funds ownership: 67.79% → 73.35% (+5.6%)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
3% less funds holding
Funds holding: 87 → 84 (-3)
31% less capital invested
Capital invested by funds: $317M → $220M (-$96.9M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$25.8M |
| 2 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$2.09M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.76M |
| 4 |
NM
Newtyn Management
New York
|
+$1.74M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$2.64M |
| 2 |
Walleye Capital
New York
|
-$1.64M |
| 3 |
SEI Investments
Oaks,
Pennsylvania
|
-$657K |
| 4 |
BlackRock
New York
|
-$540K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$228K |
PHAT Hedge Fund Activity: Q1 2023 in Review
84 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q1 2023, worth a combined $220M — down 31% from $317M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PHAT and 17 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 32 added.
The largest buyer was Carlyle Group, opening a new position worth an estimated $25.8M. The largest seller was Rhenman & Partners Asset Management, exiting entirely with an estimated $2.64M sold.
- 84 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q1 2023, down from 87 in Q4 2022.
- Funds reported $220M of Phathom Pharmaceuticals stock for Q1 2023, down 31% quarter-over-quarter.
- 17 funds opened new Phathom Pharmaceuticals positions in Q1 2023 and 18 closed out, a net change of -1 holder.
- The largest Phathom Pharmaceuticals buyer in Q1 2023 was Carlyle Group, an estimated $25.8M added.
- The largest Phathom Pharmaceuticals seller in Q1 2023 was Rhenman & Partners Asset Management, an estimated $2.64M sold.
Based on aggregated 13F filings for Q1 2023.